Acute Pulmonary Exacerbations of Sarcoidosis Efstratios Panselinas, MD, Marc A. Judson, MD, FCCP CHEST Volume 142, Issue 4, Pages 827-836 (October 2012) DOI: 10.1378/chest.12-1060 Copyright © 2012 The American College of Chest Physicians Terms and Conditions
Figure 1 The duration of therapy could determine the chance of relapse because sarcoidosis treatment may not affect the natural course of disease. If the duration of therapy exceeds the duration of disease activity (Therapy A), then the patient will not relapse when therapy is withdrawn. If the duration of therapy is shorter than the duration of disease activity (Therapy B), then the patient will relapse when therapy is withdrawn. (Reproduced with permission from Judson.54) CHEST 2012 142, 827-836DOI: (10.1378/chest.12-1060) Copyright © 2012 The American College of Chest Physicians Terms and Conditions
Figure 2 A proposed treatment algorithm for APES (see “Therapy for APES” section). APES = acute pulmonary exacerbations of sarcoidosis. CHEST 2012 142, 827-836DOI: (10.1378/chest.12-1060) Copyright © 2012 The American College of Chest Physicians Terms and Conditions